EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Pharmacist Intervention for Safer Prescribing in Patients With Type 2 Diabetes at High Risk

Lisa K Gilliam, Melissa M Parker, Minnie W Chen, Andrew J Karter, Richard W Grant

JAMA Network Open · 18.02.2026 · 9 (2) · e2559946

DOI: 10.1001/jamanetworkopen.2025.59946 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 18.02.2026. Verfasst von Lisa K Gilliam und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Permanente Medical Group, South San Francisco Kaiser Medical Center, South San Francisco, California. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemia, Hypoglycemic Agents, Pharmacists. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Severe hypoglycemia is a life-threatening, iatrogenic complication of diabetes medications associated with increased risks of falls, cardiovascular events, cognitive decline, and mortality.

Objective

To determine whether proactive outreach by a clinical pharmacist applying an evidence-based hypoglycemia-prevention algorithm (Hypoglycemia on a Page) would result in safer prescribing of diabetes regimens among patients with type 2 diabetes (T2D) with hypoglycemia risk. Design, Setting, and Participants This randomized clinical trial was conducted between July 20, 2023, and January 22, 2024, with follow-up outcomes collected through January 2025. The study included adults with T2D at high risk of hypoglycemia based on a validated hypoglycemia risk tool. The trial was conducted within Kaiser Permanente Northern California, a large, integrated health care delivery system.

Intervention

Patients were randomized 1:1 to either a protocol-driven outreach by a clinical pharmacist (intervention) arm or a usual care (control) arm. Main Outcome and Measure The main outcome was the comparison of the proportion of patients who were prescribed safer (less hypoglycemia-prone) diabetes regimens, defined as discontinuation of sulfonylureas and/or rapid-acting or short-acting or mixed insulins, using an intention-to-treat analysis.

Results

From an eligible population of 1204 patients, 200 were enrolled into the clinical trial. Among these, 191 patients were in the intention-to-treat cohort (mean [SD] age, 71.3 [11.5] years; 100 females [52.4%]). The 2 study arms were similar at baseline in terms of race and ethnicity, sex, mean (SD) hemoglobin A 1c (HbA 1c ) level (intervention: 8.0 [1.3]; control: 8.3 [1.8]), and number (percentage) of patients receiving insulin (intervention: 82 [85.4%]; control:85 [89.5%]) and sulfonylurea (intervention: 25 [26.0%]; control: 21 [22.1%]). At 6 months, patients in the intervention arm were more likely to be prescribed a safer diabetes regimen than those in the control arm (27 [28.1%] vs 15 [15.8%]; risk difference [RD], 12.3% [95% CI, 0.6% to 24.0%]). Patients in the intervention arm also experienced significantly fewer hypoglycemia-related emergency department or inpatient encounters (0 vs 5 [5.3%]; RD, −5.3% [95% CI, −11.8% to −1.3%]). There was no worsening of HbA 1c control in the intervention arm compared with the control arm (47 [61.8%] vs 49 [63.6%] with HbA 1c <8%; RD, −1.8% [95% CI, −17.0% to 13.5%]). Conclusions and Relevance In this randomized clinical trial, adding proactive, protocol-driven clinical pharmacist outreach into collaborative team-based care improved medication optimization and patient outcomes. This approach provides an evidence-based strategy for reducing the risk of developing severe hypoglycemia in individuals with T2D at high risk, enhancing patient safety, and potentially reducing overall health care cost. Trial Registration ClinicalTrials.gov Identifier: NCT06746714

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2HypoglycemiaHypoglycemic AgentsPharmacistsAgedFemaleHumansMaleMiddle AgedAdherence InterventionsCaliforniaAged, 80 and over

Substanzen

Hypoglycemic Agents

Autor:innen und Institutionen

  • The Permanente Medical Group, South San Francisco Kaiser Medical Center, South San Francisco, California.
  • Kaiser Permanente Northern California Division of Research, Pleasanton.

Förderung

  • NIDDK NIH HHS

Zitieren

APA

Gilliam, L. K., Parker, M. M., Chen, M. W., Karter, A. J., & Grant, R. W. (2026). Pharmacist Intervention for Safer Prescribing in Patients With Type 2 Diabetes at High Risk. JAMA Network Open, 9(2), e2559946. https://doi.org/10.1001/jamanetworkopen.2025.59946

Vancouver

Gilliam LK, Parker MM, Chen MW, Karter AJ, Grant RW. Pharmacist Intervention for Safer Prescribing in Patients With Type 2 Diabetes at High Risk. JAMA Network Open. 2026;9(2):e2559946. doi:10.1001/jamanetworkopen.2025.59946

BibTeX
@article{Gilliam2026,
  author = {Gilliam, Lisa K and Parker, Melissa M and Chen, Minnie W and Karter, Andrew J and Grant, Richard W},
  title = {Pharmacist Intervention for Safer Prescribing in Patients With Type 2 Diabetes at High Risk},
  journal = {JAMA Network Open},
  year = {2026},
  volume = {9},
  number = {2},
  pages = {e2559946},
  doi = {10.1001/jamanetworkopen.2025.59946}
}
Kostenlos starten →